Volume 64, Issue 5, Pages (November 2013)

Slides:



Advertisements
Similar presentations
The PSA Era is not Over for Prostate Cancer
Advertisements

Volume 64, Issue 6, Pages (December 2013)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 4, Issue 5, Pages (September 2017)
Volume 70, Issue 4, Pages (October 2016)
Volume 70, Issue 5, Pages (November 2016)
Volume 62, Issue 5, Pages (November 2012)
Volume 64, Issue 6, Pages (December 2013)
Potential and Limitations of Diffusion-Weighted Magnetic Resonance Imaging in Kidney, Prostate, and Bladder Cancer Including Pelvic Lymph Node Staging:
Volume 70, Issue 1, Pages (July 2016)
Prostate Cancer: Highlights from 2006
Volume 199, Issue 1, Pages (January 2018)
Jaden D. Evans, MD, Krishan R
Volume 73, Issue 5, Pages (May 2018)
Volume 74, Issue 2, Pages (August 2018)
Volume 54, Issue 4, Pages (October 2008)
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.
Volume 67, Issue 3, Pages (March 2015)
Volume 53, Issue 5, Pages (May 2008)
Volume 51, Issue 4, Pages (April 2007)
Managing Nonmetastatic Castration-resistant Prostate Cancer
Volume 62, Issue 2, Pages (August 2012)
Volume 71, Issue 1, Pages (January 2017)
Volume 64, Issue 6, Pages (December 2013)
Volume 55, Issue 4, Pages (April 2009)
Advances in the Treatment of Metastatic Prostate Cancer
Volume 71, Issue 5, Pages (May 2017)
Volume 64, Issue 6, Pages (December 2013)
Volume 72, Issue 5, Pages (November 2017)
Volume 70, Issue 4, Pages (October 2016)
Volume 64, Issue 5, Pages (November 2013)
Volume 70, Issue 3, Pages (September 2016)
What is New in Hormone Therapy for Prostate Cancer in 2007?
Volume 53, Issue 4, Pages (April 2008)
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Volume 68, Issue 3, Pages (September 2015)
Volume 62, Issue 1, Pages (July 2012)
Volume 71, Issue 5, Pages (May 2017)
Volume 67, Issue 4, Pages (April 2015)
Volume 64, Issue 6, Pages (December 2013)
The PSA Era is not Over for Prostate Cancer
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
11C-Choline Positron Emission Tomography for the Evaluation after Treatment of Localized Prostate Cancer  I.J de Jong, J Pruim, P.H Elsinga, W Vaalburg,
PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA–targeted PET Imaging Studies  Steven P. Rowe, Kenneth J.
European Urology Oncology
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study  Stephen H. Culp, Paul.
Volume 50, Issue 5, Pages (November 2006)
Volume 53, Issue 1, Pages (January 2008)
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006  Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,
Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation.
Volume 66, Issue 6, Pages (December 2014)
Nat. Rev. Urol. doi: /nrurol
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Long-Term Hormonal Therapy: Who Would Benefit?
Intramedullary Reactive Fibrosis as Mimic of Prostate Cancer Bone Metastasis on 11C- Choline Positron Emission and Computed Tomography  Tyler Trump, BS,
European Urology Oncology
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Volume 69, Issue 1, Pages (January 2016)
Axel Heidenreich  European Urology Supplements 
Volume 52, Issue 2, Pages (August 2007)
Volume 53, Issue 6, Pages (June 2008)
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Axel Heidenreich  European Urology Supplements 
Constantinos Zamboglou, Matthias Eiber, Thomas R
Volume 4, Issue 1, Pages (February 2006)
Volume 51, Issue 5, Pages (May 2007)
European Urology Oncology
Introduction European Urology Supplements
Presentation transcript:

Volume 64, Issue 5, Pages 862-864 (November 2013) Hybrid Positron Emission Tomography–Magnetic Resonance Imaging with Gallium 68 Prostate-specific Membrane Antigen Tracer: A Next Step for Imaging of Recurrent Prostate Cancer—Preliminary Results  Matthias C. Roethke, Timur H. Kuru, Ali Afshar-Oromieh, Heinz-Peter Schlemmer, Boris A. Hadaschik, Michael Fenchel  European Urology  Volume 64, Issue 5, Pages 862-864 (November 2013) DOI: 10.1016/j.eururo.2013.08.003 Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 1 (A, C) A 60-yr-old patient with Gleason 9 prostate cancer (PCa) after radical prostatectomy (RP) and external-beam radiation therapy (EBRT); actual prostate-specific antigen (PSA) was 3.04 ng/ml. (a, arrows) Axial T2-weighted magnetic resonance imaging (MRI) of the pelvis showing normal-sized, nonsuspicious iliac lymph nodes. (C, arrows) Corresponding gallium 68 (68Ga) prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/MRI fusion demonstrates 68Ga-PSMA tracer accumulation, representing lymph node metastases. (B, D) A 60-yr-old patient after EBRT and androgen-deprivation therapy; actual PSA was 63 ng/ml. (B, arrow) Axial T2-weighted MRI of the pelvis depicts a slightly hypointense lesion in the anterior column of the right acetabulum. (D, arrow) 68Ga-PSMA PET/MRI fusion image in identical orientation reveals a high tracer accumulation, representing a bone metastasis. Note physiologic tracer accumulation in the bladder lumen and urethra. European Urology 2013 64, 862-864DOI: (10.1016/j.eururo.2013.08.003) Copyright © 2013 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.